Nasopharyngeal carriage and macrolide resistance in Indigenous children with bronchiectasis randomized to long-term azithromycin or placebo

No abstract is available for this paper.

• Publication year

  2015

• Venue

  European Journal of Clinical Microbiology and Infectious Diseases

• Publication date

  2015-09-12

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1007/s10096-015-2480-0PMID 26363637
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• What is behind the ear drum? The microbiology of otitis media and the nasopharyngeal flora in children in the era of pneumococcal vaccination

  2014cited by this paper
• Progressive increase in community-associated methicillin-resistant Staphylococcus aureus in Indigenous populations in northern Australia from 1993 to 2012

  2014cited by this paper
• Indigenous children from three countries with non‐cystic fibrosis chronic suppurative lung disease/bronchiectasis

  2014cited by this paper
• Resistance Development of Cystic Fibrosis Respiratory Pathogens When Exposed to Fosfomycin and Tobramycin Alone and in Combination under Aerobic and Anaerobic Conditions

  2013cited by this paper
• Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.

  2013cited by this paper
• Longitudinal Nasopharyngeal Carriage and Antibiotic Resistance of Respiratory Bacteria in Indigenous Australian and Alaska Native Children with Bronchiectasis

  2013cited by this paper
• Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group.

  2013cited by this paper
• Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.

  2013cited by this paper
• Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment.

  2013cited by this paper
• Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.

  2013influential reference
• Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.

  2012cited by this paper
• Varying fitness cost associated with resistance to fluoroquinolones governs clonal dynamic of methicillin-resistant Staphylococcus aureus

  2012cited by this paper
• The Fitness Cost of Antibiotic Resistance in Streptococcus pneumoniae: Insight from the Field

  2012cited by this paper
• Fitness cost: a bacteriological explanation for the demise of the first international methicillin-resistant Staphylococcus aureus epidemic.

  2012cited by this paper
• Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial

  2012cited by this paper
• Impact of recent antibiotics on nasopharyngeal carriage and lower airway infection in Indigenous Australian children with non-cystic fibrosis bronchiectasis.

  2012cited by this paper
• Viability of respiratory pathogens cultured from nasopharyngeal swabs stored for up to 12 years at -70°C in skim milk tryptone glucose glycerol broth.

  2011cited by this paper
• Ahlstrand E , Persson L , Tidefelt U , Söderquist B. Alteration of the colonization pattern of coagulase-negative staphylococci in patients undergoing treatment for hematological malignancy. Eur J Clin Microbiol Infect Dis

  2011cited by this paper
• Do New Zealand children with non‐cystic fibrosis bronchiectasis show disease progression?

  2011cited by this paper
• Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian indigenous children with bronchiectasis.

  2010cited by this paper
• Swab transport in Amies gel followed by frozen storage in skim milk tryptone glucose glycerol broth (STGGB) for studies of respiratory bacterial pathogens.

  2010cited by this paper
• Antimicrobial susceptibility of Moraxella catarrhalis isolated from children in Kalgoorlie–Boulder, Western Australia

  2010cited by this paper
• The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma.

  2010cited by this paper
• Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines

  2010cited by this paper
• Mortality in bronchiectasis: a long-term study assessing the factors influencing survival

  2009cited by this paper
• Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.

  2009cited by this paper
• Bronchiectasis in Central Australia: a young face to an old disease.

  2008cited by this paper
• Simpson's Paradox, Lord's Paradox, and Suppression Effects are the same phenomenon – the reversal paradox

  2008cited by this paper
• “Let's not talk about sex”: reconsidering the public health approach to sexually transmissible infections in remote Indigenous populations in Australia

  2008cited by this paper
• “Let's not talk about sex”: reconsidering the public health approach to sexually transmissible infections in remote Indigenous populations in Australia

  2008cited by this paper
• Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study.

  2007cited by this paper
• Maintenance Azithromycin Treatment in Pediatric Patients With Cystic Fibrosis: Long-Term Outcomes Related to Macrolide Resistance and Pulmonary Function

  2007cited by this paper
• Better late than never: a national approach to trachoma control

  2006cited by this paper
• Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis.

  2006cited by this paper
• A multi-method assessment of treatment adherence for children with cystic fibrosis.

  2006cited by this paper
• BSAC standardized disc susceptibility testing method (version 8).

  2004cited by this paper
• Variations in Patients’ Adherence to Medical Recommendations: A Quantitative Review of 50 Years of Research

  2004cited by this paper
• Effects of an Efflux Mechanism and Ribosomal Mutations on Macrolide Susceptibility of Haemophilus influenzae Clinical Isolates

  2003cited by this paper
• High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains.

  2003cited by this paper
• Paediatric bronchiectasis in the twenty‐first century: Experience of a tertiary children's hospital in New Zealand

  2003cited by this paper
• A randomised , double-blind, placebo-controlled study

  2001cited by this paper
• Subgroup analysis and other (mis)uses of baseline data in clinical trials.

  2000cited by this paper
• Carbon dioxide requirements of Streptococcus pneumoniae and Haemophilus influenzae.

  1998cited by this paper
• A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae.

  1997cited by this paper
• Antibiotic susceptibility testing by a standardized single disk method.

  1966cited by this paper
• Antibiotic susceptibility testing by a standardized single disk method.

  1966cited by this paper

• Antimicrobial resistance in chronic lung infection: the road to resistance

  2025cites this paper
• Adherence to Anti‐Staphylococcal Prophylaxis in the First Two Years of Life and Microbiological Outcomes in the First Six Years of Life in Children With Cystic Fibrosis

  2025cites this paper
• Weekly azithromycin for 48 weeks impacts nasopharyngeal microbial prevalence and Streptococcus pneumoniae serotypes in children with HIV-associated chronic lung disease

  2025cites this paper
• Azithromycin to prevent acute lower respiratory infections among Australian and New Zealand First Nations and Timorese children (PETAL trial): study protocol for a multicentre, international, double-blind, randomised controlled trial

  2025cites this paper
• A Pilot Study Evaluating the Impact of an Algorithm-Driven Protocol on Guideline-Concordant Antibiotic Prescribing in a Rural Primary Care Setting

  2025cites this paper
• Addressing the overlooked frontier in AMR research and surveillance

  2025cites this paper
• Long-term Azithromycin Prophylaxis in Pediatric Respiratory Disorders: A Narrative Review and Applications in Hong Kong

  2025cites this paper
• A scoping review of ear and hearing health research in Aotearoa New Zealand: a focus on equity

  2025cites this paper
• Therapeutic Management of Bronchiectasis in Children and Adolescents: A Concise Narrative Review

  2024cites this paper
• Efficacy and safety of macrolides in the treatment of children with bronchiectasis: a meta-analysis

  2023influential citation
• Is all that glitters gold? Assessing the quality and ethics of ‘gold standard’ randomised controlled trials conducted in Aboriginal and Torres Strait Islander settings

  2023cites this paper
• Exploring the Reported Strengths and Limitations of Aboriginal and Torres Strait Islander Health Research: A Narrative Review of Intervention Studies

  2023cites this paper
• Impact of prophylactic and ‘rescue pack’ antibiotics on the airway microbiome in chronic lung disease

  2023cites this paper
• Long-term azithromycin in children with bronchiectasis unrelated to cystic fibrosis: treatment effects over time.

  2022cites this paper
• Antibiotic resistance in chronic respiratory diseases: from susceptibility testing to the resistome

  2022cites this paper
• Reducing exacerbations in children and adults with primary ciliary dyskinesia using erdosteine and/or azithromycin therapy (REPEAT trial): study protocol for a multicentre, double-blind, double-dummy, 2×2 partial factorial, randomised controlled trial

  2022cites this paper
• Vulnerability and antimicrobial resistance

  2022cites this paper
• Quality standards for managing children and adolescents with bronchiectasis: an international consensus

  2022cites this paper
• Management of children and adolescents with bronchiectasis: summary of the ERS clinical practice guideline

  2021cites this paper
• European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis

  2021cites this paper
• Impact of Long-Term Azithromycin Therapy on Carriage and Resistance of Respiratory Bacteria Among Children with HIV-Associated Chronic Lung Disease: A Randomised Controlled Trial

  2021cites this paper
• The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease

  2021cites this paper
• Antimicrobial stewardship in rural and remote primary health care: a narrative review

  2021cites this paper
• BTS guideline on long-term macrolides in adults with respiratory disease: not quite a panacea

  2020cites this paper
• Azithromycin Prescribing by Respiratory Pediatricians in Australia and New Zealand for Chronic Wet Cough: A Questionnaire-Based Survey

  2020cites this paper
• British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease

  2020cites this paper
• Antimicrobial susceptibility and impact of macrolide antibiotics on Moraxella catarrhalis in the upper and lower airways of children with chronic endobronchial suppuration.

  2019cites this paper
• An urgent need for antimicrobial stewardship in Indigenous rural and remote primary health care

  2019cites this paper
• Pharmacotherapeutic strategies for treating bronchiectasis in pediatric patients

  2019cites this paper
• An approach to the child with a wet cough.

  2019cites this paper
• Contemporary management of bronchiectasis in children

  2019cites this paper
• The pharmacological treatment of bronchiectasis

  2018cites this paper
• Should Antibiotic Prophylaxis Be Routinely Used in Patients with Antibody-Mediated Primary Immunodeficiency?

  2018cites this paper
• Previous antibiotic exposure and antibiotic resistance of commensal Staphylococcus aureus in Spanish primary care

  2018cites this paper
• Macrolide antibiotics for bronchiectasis.

  2018cites this paper
• Impact of Long-Term Erythromycin Therapy on the Oropharyngeal Microbiome and Resistance Gene Reservoir in Non-Cystic Fibrosis Bronchiectasis

  2018cites this paper
• The clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: A multi-centre, double-blind, randomised controlled trial

  2018cites this paper
• Bronchiectasis: Treatment decisions for pulmonary exacerbations and their prevention

  2018cites this paper
• Bronchiectasis in children: diagnosis and treatment.

  2018cites this paper
• Amoxicillin–clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial

  2018cites this paper
• Bronchiectasis and Chronic Suppurative Lung Disease

  2018cites this paper
• Assessment of Pseudomonas aeruginosa epidemiology and the wider microbial diversity within the bronchiectatic lung

  2018cites this paper
• CHANG Bronchiectasis : Treatment decisions for pulmonary exacerbations and their prevention

  2018cites this paper
• INVITED REVIEW SERIES: PAEDIATRIC AND ADULT BRONCHIECTASIS

  2018cites this paper
• Survey about the use of clarithromycin in an ENT outpatient department of a tertiary hospital

  2017cites this paper
• The Likelihood of Preventing Respiratory Exacerbations in Children and Adolescents with either Chronic Suppurative Lung Disease or Bronchiectasis

  2017cites this paper
• An update on pediatric bronchiectasis

  2017cites this paper
• Persistent and Recurrent Bacterial Bronchitis—A Paradigm Shift in Our Understanding of Chronic Respiratory Disease

  2017cites this paper
• ERS statement on protracted bacterial bronchitis in children

  2017cites this paper
• Streptococcus pneumoniae and chronic endobronchial infections in childhood

  2017influential citation
• Acquired macrolide resistance genes in nontypeable Haemophilus influenzae

  2017cites this paper
• Defining lower airway bacterial infection in children with chronic endobronchial disorders

  2017cites this paper
• Bronchiectasis in Children: Current Concepts in Immunology and Microbiology

  2017influential citation
• Recurrent Acute Rhinosinusitis Prevention by Azithromycin in Children with Nonallergic Rhinitis.

  2017cites this paper
• Long-term antibiotic treatment for non-cystic fibrosis bronchiectasis in adults: evidence, current practice and future use

  2016cites this paper
• Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults.

  2015cites this paper
• Adverse events in people taking macrolide antibiotics versus placebo for any indication.

  2015cites this paper